[Heparin-Induced Thrombocytopenia after Total Knee Replacement]

Area of Science:

• Cardiology
• Hematology
• Orthopedic Surgery

Background:

• Heparin-induced thrombocytopenia (HIT) is a rare immune-mediated complication associated with unfractionated heparin (UFH) and low molecular weight heparin (LMWH).
• Pathogenesis involves antibodies against the heparin-platelet factor 4 complex, leading to platelet activation and a prothrombotic state.
• HIT can manifest as both venous and arterial thrombosis, with potential for severe outcomes including limb ischemia, myocardial infarction, and stroke.

Observation:

• A case report details a patient who developed HIT following primary knee replacement surgery.
• The patient had received nadroparin preoperatively for atrial fibrillation.
• Notably, this patient presented with HIT without evidence of venous thromboembolic disease.

Findings:

• Early diagnosis of HIT requires a combination of clinical assessment (e.g., 4T score) and laboratory testing.
• Immediate cessation of UFH or LMWH is essential.
• Switching to non-heparin anticoagulants such as fondaparinux, bivalirudin, or argatroban is the recommended treatment strategy.

Implications:

• Effective management of HIT involves prompt diagnosis and appropriate anticoagulant substitution, as demonstrated by the case transitioning from nadroparin to fondaparinux and then warfarin.
• Understanding HIT is critical for orthopedic surgery patients, especially those with pre-existing conditions like atrial fibrillation requiring anticoagulation.
• This case highlights the importance of considering HIT in post-operative patients on heparin, even in the absence of typical venous thromboembolic presentations.